SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001193125-21-051450
Filing Date
2021-02-23
Accepted
2021-02-23 06:50:31
Documents
14
Period of Report
2021-02-23
Items
Item 2.02: Results of Operations and Financial Condition
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K d96654d8k.htm   iXBRL 8-K 25934
2 EX-99.1 d96654dex991.htm EX-99.1 112277
6 GRAPHIC g96654page1.jpg GRAPHIC 7920
  Complete submission text file 0001193125-21-051450.txt   285674

Data Files

Seq Description Document Type Size
3 XBRL TAXONOMY EXTENSION SCHEMA epzm-20210223.xsd EX-101.SCH 3066
4 XBRL TAXONOMY EXTENSION LABEL LINKBASE epzm-20210223_lab.xml EX-101.LAB 18138
5 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE epzm-20210223_pre.xml EX-101.PRE 11405
7 EXTRACTED XBRL INSTANCE DOCUMENT d96654d8k_htm.xml XML 3342
Mailing Address 400 TECHNOLOGY SQUARE 4TH FLOOR CAMBRIDGE MA 02139
Business Address 400 TECHNOLOGY SQUARE 4TH FLOOR CAMBRIDGE MA 02139 617-229-5872
Epizyme, Inc. (Filer) CIK: 0001571498 (see all company filings)

IRS No.: 261349956 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-35945 | Film No.: 21663002
SIC: 2834 Pharmaceutical Preparations